Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in Metastatic Colorectal Cancer

Event summary

  • Pfizer’s BRAFTOVI regimen (encorafenib + cetuximab + FOLFIRI) nearly doubled median progression-free survival (15.2 months vs. 8.3 months) in metastatic colorectal cancer (mCRC) with BRAF V600E mutation.
  • The Phase 3 BREAKWATER trial showed a 56% reduction in disease progression or death risk (HR 0.44, p=0.0002) and a 44% reduction in death risk (HR 0.56).
  • FDA granted full approval for the expanded indication in February 2026, allowing flexibility in chemotherapy regimens.
  • Results were presented at the 2026 ASCO Annual Meeting and published in the Annals of Oncology.

The big picture

Pfizer’s BRAFTOVI regimen solidifies its position in precision oncology, addressing a high-unmet need in BRAF V600E-mutant mCRC. The approval and positive trial results come as the biopharma industry increasingly focuses on targeted therapies for rare cancer mutations. Pfizer’s ability to leverage this success could influence its oncology portfolio strategy and competitive standing in the rapidly evolving cancer treatment landscape.

What we're watching

Market Adoption
The pace at which oncologists adopt BRAFTOVI as a standard of care for BRAF V600E-mutant mCRC will determine its commercial success.
Competitive Dynamics
Whether Pfizer can sustain its lead in this niche given potential competitive responses from other targeted therapies in development.
Regulatory Expansion
How quickly Pfizer can secure approvals in other regions, particularly Europe and Asia, to maximize global reach.